The price of deuterocelexitinib is affected by region, dosage, and health insurance policies. Specific costs should be confirmed with your local hospi···【Read More】
Update: 2026-03-31Source: Haiou HealthViews: 99
Deuterocactinib is an oral targeted therapy primarily used to treat moderate to severe plaque psoriasis and other immune-related diseases. Its price f···【Read More】
Update: 2026-03-31Source: Haiou HealthViews: 107
The current domestic price of deuterocelexitinib (14 tablets) is approximately 4300-4800 RMB per box (14 tablets). The specific price may fluctuate sl···【Read More】
Update: 2026-03-31Source: Haiou HealthViews: 95
Bristol-Myers Squibb (BMS) recently announced that the pivotal Phase 3 POETYK PSO-1 study evaluating the novel anti-inflammatory drug deucravacitinib ···【Read More】
Update: 2026-03-31Source: Haiou HealthViews: 106
On September 9, 2022, Bristol-Myers Squibb announced that the US Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the tre···【Read More】
Update: 2026-03-31Source: Haiou HealthViews: 97
On September 9, 2022, Bristol-Myers Squibb announced that the US Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the tre···【Read More】
Update: 2026-03-31Source: Haiou HealthViews: 98
Bristol-Myers Squibb announced on September 9, 2022, that the U.S. Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the t···【Read More】
Update: 2026-03-31Source: Haiou HealthViews: 104
The European Commission (EC) recently approved Bristol-Myers Squibb's Sotyktu (deucravacitinib) as a once-daily oral tablet for the treatment of a···【Read More】
Update: 2026-03-31Source: Haiou HealthViews: 109
Bristol-Myers Squibb recently announced that the US Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the treatment of act···【Read More】
Update: 2026-03-31Source: Haiou HealthViews: 91
Seattle Genetics recently announced that Australian regulatory authorities have approved TUKYSA® (tucatinib) in combination with trastuzumab and capec···【Read More】
Update: 2026-03-27Source: Haiou HealthViews: 93
Seattle Genetics recently announced that Australian regulatory authorities have approved TUKYSA® (tucatinib) in combination with trastuzumab and capec···【Read More】
Update: 2026-03-27Source: Haiou HealthViews: 94
On April 17, 2020, the U.S. Food and Drug Administration (FDA) approved the new breast cancer drug Tukysa in combination with trastuzumab (Herceptin) ···【Read More】
Update: 2026-03-27Source: Haiou HealthViews: 100
On July 2, 2022, Seagen announced the full results of the pivotal Phase 2 MOUNTAINEER trial, demonstrating that tucatinib (trademark: TUKYSA) in combi···【Read More】
Update: 2026-03-27Source: Haiou HealthViews: 95
The price of Eltrombopag varies depending on factors such as specifications, dosage form, and whether it is imported or domestically produced. It typi···【Read More】
Update: 2026-03-27Source: Haiou HealthViews: 93
The price of eltrombopag (generic name: eltrombopag ethanolamine tablets) varies depending on factors such as specifications, origin, and purchase cha···【Read More】
Update: 2026-03-27Source: Haiou HealthViews: 96
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos



